CNS-3D Brain Organoids at the Society for Toxicology (SOT) 65th Annual Meeting in San Diego, CA, March 22-25, 2026.

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced microRNA Clinical Programs GLASGOW, Scotland, March 19, 2026 (GLOBE NEWSWIRE) -- Causeway ...

Innovative Medical Equipment, LLC (IME), manufacturer of the ThermaZone® thermal therapy device, announced the publication of ...

A Finnish clinical imaging study shows that rest tremor in Parkinson's disease is not explained by greater dopamine loss. In ...

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

A new study published in the Journal of Allergy and Clinical Immunology has traced how the sympathetic nervous system, the ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and ...

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts (TMCI), Inc. , a medical technology company driving a fundamental shift in the surgical treatment of bunions and related ...

Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a ...